The average one-year price target for Editas Medicine (NASDAQ:EDIT) has been revised to 13.68 / share. This is an increase of 5.56% from the prior estimate of 12.96 dated June 1, 2023. The price ...
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely ...
Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial performance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback